Quarterly ResultMay 15, 2026, 04:24 PM
Rani Therapeutics Q1 Net Loss Narrows to $8.0M; Revenue Jumps to $1.7M
AI Summary
Rani Therapeutics reported a net loss of $8.0 million for Q1 2026, a significant improvement from $12.7 million in Q1 2025. Contract revenue surged to $1.7 million, up from $0.17 million in the prior year, largely due to the Chugai collaboration. The company maintains $43.4 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 narrowed to $8.0 million, down from $12.7 million in Q1 2025.
- Contract revenue for Q1 2026 increased significantly to $1.7 million, from $0.17 million in Q1 2025.
- Research and development expenses decreased to $5.2 million in Q1 2026 from $6.6 million in Q1 2025.
- General and administrative expenses fell to $4.9 million in Q1 2026 from $5.6 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $43.4 million as of March 31, 2026.
- Net cash used in operating activities was $6.5 million for Q1 2026, an improvement from $8.1 million in Q1 2025.
- The company expects its current cash to fund operations for at least the next twelve months.
- Accumulated deficit reached $139.6 million as of March 31, 2026.
Price Impact
More from RANI